29
Screening Test for Occult Cancer 100 patients with occult cancer: 95 have "x" in their blood 100 patients without occult cancer: 95 do not have "x" in their blood 5 out of every 1000 randomly selected individuals will have occult cancer SENSITIVITY SPECIFICITY PREVALENCE

Screening Test for Occult Cancer

Embed Size (px)

DESCRIPTION

Screening Test for Occult Cancer. 100 patients with occult cancer: 95 have "x" in their blood 100 patients without occult cancer: 95 do not have "x" in their blood 5 out of every 1000 randomly selected individuals will have occult cancer. SENSITIVITY. SPECIFICITY. PREVALENCE. - PowerPoint PPT Presentation

Citation preview

Page 1: Screening Test for Occult Cancer

Screening Test for Occult Cancer

100 patients with occult cancer: 95 have "x" in their blood

100 patients without occult cancer: 95 do not have "x" in their blood

5 out of every 1000 randomly selected individuals will have occult cancer

SENSITIVITY

SPECIFICITY

PREVALENCE

Page 2: Screening Test for Occult Cancer

2 X 2 Table

Occult CancerPresent

Occult CancerAbsent

"x" present "x" absent

100,000

99,500

50025475

4,975 94,525

5,450 94,550

If a patient has “x” in his blood, chance of occult canceris 475 / 5450 = 8.7%

Page 3: Screening Test for Occult Cancer

Standard Terminology

DiseasePresent

DiseaseAbsent

Test positive

Testnegative

EntirePopulation

FP + TN

TP + FNTrue

Positives(TP’s)

FalsePositives

(FP’s)

TrueNegatives

(TN’s)

FalseNegatives

(FN’s)

TP + FP FN + TN

Page 4: Screening Test for Occult Cancer

Definitions

SENSITIVITY = TPTP + FN

= P(T+|D+)

SPECIFICITY = TNFP + TN

= P(T -|D-)

PV + = PREDICTIVE VALUE = TPTP + FP

= P(D+|T+)

Page 5: Screening Test for Occult Cancer

Positive Predictive Value Formula

(Sens)(Prev) + (1-Spec)(1-Prev)PV+ =

(Sens)(Prev)

Page 6: Screening Test for Occult Cancer

Detection of Prostatic Cancer by Solid-Phase Radioimmunoassay of Serum Prostatic Acid Phosphatase

Page 7: Screening Test for Occult Cancer

Editorial

“The clear implication of the accompanying report is that mass screening on the basis of a blood test alone can reverse this gloomy experience [of fatal delays in diagnosis of prostate cancer].”

New England Journal of MedicineDecember 22, 1977

Page 8: Screening Test for Occult Cancer

Medical Journal

Advertisement to Physicians

Page 9: Screening Test for Occult Cancer

Medical Journal

Advertisement to Physicians

Posed by a Professional Model

Page 10: Screening Test for Occult Cancer

Medical Journal

Advertisement to Physicians

Page 11: Screening Test for Occult Cancer

Advertisement

“(You should be aware of) a new blood test called the Male-P.A.P. test ... a new, more sensitive method that your physician can use to detect chemical signals of a cancerous growth in the prostate. ... And even though all lab tests must be ordered by a physician, we believe that you should know the facts.”

New York Times, January 21, 1979

Page 12: Screening Test for Occult Cancer

Sensitivity

Patients with prostate 113 79 70%cancer

Stage I 24 8 33%

Stage II 33 26 79%

Stage III 31 22 71%

Stage IV 25 23 92%

# ofpatients

# of positivetests

sensitivity

Page 13: Screening Test for Occult Cancer

Specificity

Patients without prostate 217 13 94%cancer

Normal controls 50 0

BPH 36 2

After total prosta- 28 1tectomy

Other cancers 83 9

Misc. GI disorders 20 1

# ofpatients

# of positivetests

specificity

Page 14: Screening Test for Occult Cancer

Use As Screening Test

• Without rectal examination:–Sensitivity = 70% Specificity = 94%

–Prevalence 33/100,000

–PV+ = 0.41% (i.e., 1 in 244 subjects)

• With rectal examination:–Sensitivity = 33% Specificity = 94%

–Prevalence 33/100,000

–PV+ = 0.19% (i.e., 1 in 526 subjects)

Page 15: Screening Test for Occult Cancer

When is the test useful for screening?

Suppose patient has a nodule on rectal examination:

–Sensitivity (Stage 2 of disease) = 79%

–Specificity = 94%

–Prevalence = 50% !!

PV+ = 93% (chance of cancer if acid phosphatase is positive)

PV- = 82% (chance that there is no cancer if acid phosphatase is negative)

Page 16: Screening Test for Occult Cancer

Predictive Values in Patients with a Nodule

PAP+

PAP-

50%

93%

18%

Page 17: Screening Test for Occult Cancer

Combining Tests For Screening:

If a prostate biopsy is now performed, it needs to be considered as another test.

Specificity = 100%

Sensitivity depends on talent and statistics of surgeon doing the procedure

Prevalence is 50% if acid phosphatase has not been measured, but is 93% if acid phosphatase is positive and 18% if acid phosphatase is negative.

Page 18: Screening Test for Occult Cancer

Sequential Testing

PAP+

PAP-

50%

93%

18%

BX+

BX+

100%

100%

Page 19: Screening Test for Occult Cancer

Chance of Cancer after Negative Biopsy

Sensitivity of Biopsy

Acid Phosphatase positive (93% chance before biopsy)

Acid Phosphatase negative (18% chance before biopsy)

50%

87%

10%

70%

80%

6%

90%

56%

2%

Page 20: Screening Test for Occult Cancer

Sequential Testing

PAP+

PAP-

50%

93%

18%

BX+

BX+

BX-

BX-

100%

100%

56%

< 2%

Page 21: Screening Test for Occult Cancer

BAYES’ THEOREM

OR

P(D+|T+) = P(T+|D+) P(D+)P(T+|D+) P(D+) + [1-P(T -|D-)] [1- P(D+)]

PV + = (Sens )(Prev )(Sens )(Prev ) + (1-Spec )(1-Prev )

Page 22: Screening Test for Occult Cancer

Typical Assumptions with theUse of Bayes' Theorem

• Completeness (for example, all men either have or do not have prostate cancer; there are no other possibilities)

• Mutual exclusivity (for example, if a man has prostate cancer, he cannot simultaneously NOT have prostate cancer)

• Conditional independence (for example, acid phosphatase and a biopsy result ARE conditionally independent tests; rectal exams and acid phosphatase may NOT be conditionally independent)

Page 23: Screening Test for Occult Cancer

References

Foti et al. “Detection of prostate cancer by solid-phase radioimmunoassay of serum prostatic acid phosphatase.” New England Journal of Medicine 297:1357-1361 (1977)

Watson, R.A. and Tang, D.B. “The predictive value of prostatic acid phosphatase as a screening test for prostatic cancer.” New England Journal of Medicine 303:497-499 (1980)

Berwick, D.M., Fineberg, H.V., and Weinstein, M.C. “When doctors meet numbers.” American Journal of Medicine 71:991 (1981)

Page 24: Screening Test for Occult Cancer

What is a “Positive Test”?

• All the analysis has assumed that it is clear whether a test is positive or negative

• In reality, many tests involve continuous values so that one result may be “more positive” than another

• How should one define the cut-off at which a test is judged to be abnormal?

Page 25: Screening Test for Occult Cancer

Continuously Valued Variables

Normal

Diseased

Result

“Normal” cutoff False

Positives

False Negatives

True Negatives

True Positives

Page 26: Screening Test for Occult Cancer

Continuously Valued Variables

Normal

Diseased

Result

“Normal” cutoff

• Fewer false positives (more “conservative”)

• More false negatives• Higher specificity• Lower sensitivity

Page 27: Screening Test for Occult Cancer

Continuously Valued Variables

Normal

Diseased

Result

“Normal” cutoff

• Fewer false negatives (more “aggressive”)

• More false positives• Higher sensitivity• Lower specificity

Page 28: Screening Test for Occult Cancer

Receiver Operating Characteristic(ROC) Curves

Tru

e P

osi

tive

Rat

e =

Sen

siti

vity

False Positive Rate = 1 - Specificity

Test ATest B

ROC curve shifts to left, indicating the new test (B) is “better” – or a better indicator to disease presence (more discriminatory).

Page 29: Screening Test for Occult Cancer

The Importance of the Gold Standard

• Evaluating the value of a new test requires having some other method for determining “truth”

• Methods for determining truth are called gold standards

• Gold standards are often expensive, time consuming, uncomfortable, or risky– Biopsies

– Major invasive procedures or surgery

– Autopsies

– Integrated opinions of “super experts”

• We often seek simple, inexpensive, rapid, and safe tests that can perform almost as well as the gold standard